Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 18/20 | 0.68 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19292677 | 1.00 | DGAT1 (0.68) | DGAT1JAK2SYK | |
| SCHEMBL13664077 | 1.00 | DGAT1 (0.68) | DGAT1JAK2SYK | |
| SCHEMBL14617030 | 1.00 | DGAT1 (0.68) | DGAT1JAK2SYK | |
| SCHEMBL15872159 | 0.99 | DGAT1 (0.67) | DGAT1JAK2SYK | |
| Potassium Ion SCHEMBL15872162 | 0.91 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL15872172 | 0.91 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL15872161 | 0.91 | DGAT1 (0.58) | DGAT1 | |
| Potassium Ion SCHEMBL15872163 | 0.91 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL180880 | 0.91 | DGAT1 (0.58) | DGAT1 | |
| SCHEMBL15872177 | 0.91 | DGAT1 (0.58) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2943488-B1 | MEGLUMINE SALT FORMS OF 2-((1 R,4R)-4-(4-(5-(BENZOXAZOL-2-YLAMINO)PYRIDIN-2-YL)PHENYL)CYCLOHEXYL) ACETIC ACID AND THEIR USE AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2018-03-28 | — | — | EP | claimed |
| EP-2402319-B1 | DGAT Inhibitors | NOVARTIS AG (CH) | 2017-08-30 | — | — | EP | claimed |
| US-9242971-B2 | Compounds for the treatment of conditions associated with DGAT1 activity | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | claimed |
| EP-2943488-A1 | MEGLUMINE SALT FORMS OF 2-((1 R,4R)-4-(4-(5-(BENZOXAZOL-2-YLAMINO)PYRIDIN-2-YL)PHENYL)CYCLOHEXYL) ACETIC ACID AND THEIR USE AS DGAT1 INHIBITORS | Novartis AG (CH) | 2015-11-18 | — | — | EP | claimed |
| US-20150166522-A1 | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DGAT1 ACTIVITY | NOVARTIS AG (CH) | 2015-06-18 | — | — | US | claimed |
| US-20150065517-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | claimed |
| WO-2014110344-A1 | MEGLUMINE SALT FORMS OF 2-((1 R,4R)-4-(4-(5-(BENZOXAZOL-2-YLAMINO)PYRIDIN-2-YL)PHENYL)CYCLOHEXYL) ACETIC ACID AND THEIR USE AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-07-17 | — | — | WO | claimed |
| US-20140200246-A1 | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DGAT1 ACTIVITY | NOVARTIS AG (CH) | 2014-07-17 | — | — | US | claimed |
| WO-2013169648-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A DGAT1 INHIBTOR AND A TRIGLYCERIDE LOWERING DRUG | NOVARTIS AG (CH) | 2013-11-14 | — | — | WO | claimed |
| US-20130018054-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | claimed |
| US-20130018074-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | claimed |
| EP-2418202-A1 | New compounds | Novartis AG (CH) | 2012-02-15 | — | — | EP | claimed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | claimed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | claimed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | claimed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | claimed |
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065517-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885JAK2 4761/4885SYK 4884/4885 |
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885JAK2 4761/4885SYK 4884/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | DGAT1 1629/4885JAK2 3383/4885SYK 4212/4885 |
| US-20140200246-A1 | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DGAT1 ACTIVITY | DGAT1, DGAT2, GBA1 | DGAT1 1/4885JAK2 4823/4885SYK 4881/4885 |
| US-20130018054-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885JAK2 4755/4885SYK 4884/4885 |
| US-20150166522-A1 | COMPOUNDS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH DGAT1 ACTIVITY | DGAT1, DGAT2, GBA1 | DGAT1 1/4885JAK2 4823/4885SYK 4881/4885 |
| US-20130018074-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | DGAT1 1/4885JAK2 4755/4885SYK 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.